Literature DB >> 32244791

Identification of Toxoplasma Gondii Tyrosine Hydroxylase (TH) Activity and Molecular Immunoprotection against Toxoplasmosis.

Zhenchao Zhang1, Yuhua Li1, Haoran Li1, Xiaoxiao Song1, Zhongshan Ma1, Haoran Lu1, Shuyue Liu1, Yi Zhao1, Mengyao Tan1, Shuai Wang1, Xiangrui Li1,2.   

Abstract

The neurotropic parasite Toxoplasma gondii (T. gondii) infection can change the behavior of rodents and cause neuropsychological symptoms in humans, which may be related to the change in neurotransmitter dopamine in the host brain caused by T. gondii infection. T. gondii tyrosine hydroxylase (TgTH) is an important factor in increasing the neurotransmitter dopamine in the host brain. In this study, the enzyme activity of TgTH catalytic substrate for dopamine production and the molecular characteristics of TgTH were identified. In order to amplify the open reading frame (ORF), the designing of the specific primers for polymerase chain reaction (PCR) was on the basis of the TgTH sequence (GenBank Accession No. EU481510.1), which was inserted into pET-32a (+) for the expression of recombined TgTH (rTgTH). The sequence analysis indicated that the gene of TgTH directed the encoding of a 62.4-kDa protein consisting of 565 amino acid residues, which was predicted to have a high antigen index. The enzyme activity test showed that rTgTH and the soluble proteins extracted separately from T. gondii RH strain and PRU strain could catalyze the substrate to produce dopamine in a dose-dependent manner, and the optimum catalytic temperature was 37 °C. The result of the Western Blotting assay revealed that the rTgTH and the native TgTH extracted from somatic of T. gondii RH tachyzoite were successfully detected by the sera of mice infected with T. gondii and the rat serum after rTgTH immune, respectively. Immunofluorescence analysis using antibody against rTgTH demonstrated that the protein was expressed and located on the surface of T. gondii RH tachyzoite. Freund's adjuvant was used to emulsify the rTgTH, which was subsequently applied to BALB/c mouse immune thrice on week 0, week 2, and week 4, respectively. The result of the animal challenge experiments showed an integral increase in IgG, IgG2a, IgG1, and IFN-γ, IL-4, and IL17 were as well significantly increased, and that the rTgTH vaccinated animals apparently had a prolonged survival time (14.30 ± 2.41) after infection with the RH strain of T. gondii compared with that of the non-vaccinated control animals, which died within 11 days. Additionally, in the rTgTH vaccination group, the number of brain cysts (1275 ± 224) significantly decreased (p < 0.05) compared to the blank control group (2375 ± 883), and the size of the brain cysts in the animals immunized with rTgTH vaccination was remarkably smaller than that of the control mice. All the findings prove that TgTH played an important role in increasing the neurotransmitter dopamine in the host brain and could be used as a vaccine candidate antigen to mediate cell-mediated and humoral immunity.

Entities:  

Keywords:  T. gondii; animal challenge; catalytic activity; protective immunity; tyrosine hydroxylase

Year:  2020        PMID: 32244791     DOI: 10.3390/vaccines8020158

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  7 in total

Review 1.  Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development.

Authors:  Ki-Back Chu; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2021-04-21

2.  Genomic Medicine and Advances in Vaccine Technology and Development in the Developing and Developed World.

Authors:  Rossella Cianci; Laura Franza
Journal:  Vaccines (Basel)       Date:  2020-12-24

3.  A Novel Vaccine Candidate: Recombinant Toxoplasma gondii Perforin-Like Protein 2 Stimulates Partial Protective Immunity Against Toxoplasmosis.

Authors:  Xiaowei Tian; Hanqi Sun; Meng Wang; Guangmin Wan; Tong Xie; Xuefang Mei; Zhenchao Zhang; Xiangrui Li; Shuai Wang
Journal:  Front Vet Sci       Date:  2022-02-15

4.  Vaccination with recombinant Toxoplasma gondii bradyzoite-formation deficient 1 (rTgBFD1) antigen provides partial protective immunity against chronic T. gondii infection.

Authors:  Xiaowei Tian; Zhenke Yang; Guangmin Wan; Tong Xie; Meng Wang; Hanqi Sun; Xuefang Mei; Zhenchao Zhang; Xiangrui Li; Shuai Wang
Journal:  Front Vet Sci       Date:  2022-09-12

5.  4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-Toxoplasma gondii agents.

Authors:  Adrian Bekier; Lidia Węglińska; Agata Paneth; Piotr Paneth; Katarzyna Dzitko
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

6.  Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2.

Authors:  Yu Tao; Rui Yang; Jianhong Shu; Wenqian Zheng; Jian Chen; Yuehong Wu; Yulong He
Journal:  BMC Vet Res       Date:  2020-09-16       Impact factor: 2.741

7.  4-Arylthiosemicarbazide Derivatives as Toxoplasmic Aromatic Amino Acid Hydroxylase Inhibitors and Anti-inflammatory Agents.

Authors:  Adrian Bekier; Anna Brzostek; Agata Paneth; Bożena Dziadek; Jarosław Dziadek; Justyna Gatkowska; Katarzyna Dzitko
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.